← Oncology Approval Tracker

FDA DECISION ·

Keytruda + chemotherapy

pembrolizumab with chemotherapy · Merck

Traditional approvalTraditional conversionBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Patients with locally recurrent unresectable or metastatic triple-negative breast cancer and PD-L1 combined positive score of at least 10 by an FDA-approved test.

LAMPGEN ANALYSIS

Why it matters

This traditional conversion concerns the PD-L1-selected advanced population, separate from the same-day early-stage action.

What research teams should watch

Keep PD-L1 CPS, disease stage and treatment intent in the eligibility record.

PRIMARY RECORDS

Sources